10x Genomics
TXG · NASDAQ
Supply-chain layerSingle-cell and spatial biology
Evidence status: Verified · Reviewed 2026-07-12
Supply-chain research brief
AI Biotech Infrastructure
Map sequencing, automation, instruments, bioprocessing, compute, data, and scale-up infrastructure for AI-native biotech.
Market map
Where constraints can shape the market
AI-native biology is constrained by the cost, quality, and throughput of experimental feedback. Models need sequence and assay data, automated laboratories, reliable instruments, reagents, sample handling, bioprocessing, and compute. A digital prediction has limited value until a physical experiment can validate it and a process can reproduce it at scale.
The directory separates sequencing and omics, laboratory automation, bioprocessing consumables, cloud and data infrastructure, AI drug-discovery platforms, CRO/CDMO scale-up, and synthetic-biology screening. This distinguishes enabling infrastructure from drug developers whose economics remain tied to individual clinical assets.
Evidence is weighted by maturity: an official product or platform page supports technical relevance; a named collaboration supports workflow adoption; reported instrument placements, consumables growth, backlog, or manufacturing agreements provide stronger economic validation. Unreported AI-biotech revenue is not presented as fact.
Research universe
Supply-chain layers we track
- Sequencing & Omics4 tracked companies
- Lab Automation & Instruments7 tracked companies
- Bioprocessing & Consumables4 tracked companies
- Cloud, Compute & Data4 tracked companies
- AI Drug Discovery Platforms3 tracked companies
- CRO, CDMO & Scale-up3 tracked companies
- Synthetic Biology & Screening2 tracked companies
Public preview
Five representative companies in the research universe
Examples are sampled across supply-chain layers; ordering is not a ranking. Scores, thesis, risks and full evidence remain in the Atlas.
Agilent Technologies
A · NYSE
Supply-chain layerAnalytical instruments and laboratory software
Evidence status: Sourced · Reviewed 2026-07-12
Avantor
AVTR · NYSE
Supply-chain layerLaboratory and bioprocessing materials
Evidence status: Sourced · Reviewed 2026-07-12
Alphabet
GOOGL · NASDAQ
Supply-chain layerCloud, models and biological data platforms
Evidence status: Verified · Reviewed 2026-07-12
AbCellera Biologics
ABCL · NASDAQ
Supply-chain layerAntibody discovery platform and screening
Evidence status: Verified · Reviewed 2026-07-12
Full research access
Open all 27 companies, scores, risks, and sources.
Verify your email to use the filterable directory and review the complete evidence-backed research set.
Questions
How to read this market
What is the core AI-biotech bottleneck?
The experiment loop: generating standardized biological data, automating assays, learning from results, and translating a candidate into reproducible manufacturing.
Why include diversified tool vendors?
A diversified instrument or consumables supplier can control a critical workflow despite low pure-play exposure, so bottleneck relevance is scored separately.
Are AI drug developers infrastructure companies?
Only when their platforms generate reusable data or workflow capacity. Pipeline value and platform value are separated in the thesis and risk assessment.